Peripheral arterial thromboembolism prevention

Peripheral arterial thromboembolism prevention refers to the prophylactic inhibition of blood clot formation and subsequent vascular occlusion within non-coronary systemic arteries, most commonly targeting the lower extremities, upper extremities, or visceral vasculature This clinical state arises when localized in situ thrombi form over disrupted atherosclerotic plaques or when cardiac or proximal aortic emboli lodge in distal arterial lumens, leading to sudden or progressive perfusion deficits...

Peripheral arterial thromboembolism prevention refers to the prophylactic inhibition of blood clot formation and subsequent vascular occlusion within non-coronary systemic arteries, most commonly targeting the lower extremities, upper extremities, or visceral vasculature It predominantly affects adults with peripheral artery disease, hypercoagulable states, atrial fibrillation, or those undergoing peripheral surgical or endovascular revascularization

This clinical state arises when localized in situ thrombi form over disrupted atherosclerotic plaques or when cardiac or proximal aortic emboli lodge in distal arterial lumens, leading to sudden or progressive perfusion deficits Clinically and pathophysiologically, prevention strategies mitigate platelet activation, aggregation, and the coagulation cascade to avert acute limb ischemia, tissue necrosis, amputation, and major adverse cardiovascular events

This clinical state arises when localized in situ thrombi form over disrupted atherosclerotic plaques or when cardiac or proximal aortic emboli lodge in distal arterial lumens, leading to sudden or progressive perfusion deficits

It predominantly affects adults with peripheral artery disease, hypercoagulable states, atrial fibrillation, or those undergoing peripheral surgical or endovascular revascularization Clinically and pathophysiologically, prevention strategies mitigate platelet activation, aggregation, and the coagulation cascade to avert acute limb ischemia, tissue necrosis, amputation, and major adverse cardiovascular events

It predominantly affects adults with peripheral artery disease, hypercoagulable states, atrial fibrillation, or those undergoing peripheral surgical or endovascular revascularization